Market News AIOpen the app

Following the identification of a trial halt by a Wall Street analyst, reports emerged regarding three fatalities.

MarketRead the original at benzinga.com
Bad for BMY

Trial pause for zola-cel and a multi-month delay in publicly disclosing ICANS cases increase regulatory, timeline, and reputational risk for Bristol Myers.

BMY · Bristol Myers Squibb

AI read · Bad for BMY

The AI's read

Bristol Myers paused enrollment in its zola-cel autoimmune trial after detecting ICANS and delayed public disclosure for months, creating reputational and regulatory risk. The company argues the events were non-fatal and reversible and that regulators were notified promptly, but the disclosure delay is the dominant negative factor.

NVS · Novartis

AI read · Bad for NVS

The connection

Novartis suspended rap-cel trials after three patient deaths, creating acute safety, regulatory, and reputational damage for its cell‑therapy program.

Get alerts for BMY

Follow Bristol Myers Squibb (BMY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BMY
Free on the App Store and Google Play, or on the web.